COMPANY PROFILE

Ampersand Biomedicines

Explore full profile

Programming medicines to act only where needed

Boston, United StatesFounded 2020Biotech & Life Sciences

Valuation $100–500M Latest valuation · 2025

Headcount <100 Current team size

Total funding $100–500M Disclosed equity funding

Unlock exact values

About Ampersand Biomedicines

Ampersand Biomedicines is a biotechnology company focused on developing modular therapeutics that are localized to specific target tissues, thereby enhancing efficacy and safety in disease treatment. The company operates in the precision medicine market, addressing the critical challenge of on-target, off-tissue toxicity in drug development. Ampersand's primary clients include pharmaceutical companies and healthcare providers seeking advanced therapeutic solutions. The business model revolves around creating and programming therapeutics that combine a localizing element for disease-specific precision with an actuator for restoring healthy biology. Ampersand generates revenue through partnerships, licensing agreements, and potentially direct sales of its proprietary therapeutics. The company recently secured $50 million in funding from Flagship Pioneering to advance its platform and expand its therapeutic offerings.

Source: Dealroom company data

At a glance

Status: Operational
Founded: 2020
Headquarters: Boston, United States
Employees: 72
Open positions: 2
Dealroom signal: 89.0/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Precision Medicine, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model: Manufacturing
Investment activity: 1 company, latest Jan 2024
Capital deployed: —
Preferred round: ACQUISITION
Links: Website LinkedIn X

Latest news

Press, funding announcements and product moves mentioning Ampersand Biomedicines.

See all news

Funding history

2 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES BOther financing	Mar 2025	$65M	$260M	Flagship Pioneering · Eli Lilly	↗
LATE VCOther financing	Mar 2023	$50M	$200M	Flagship Pioneering	↗

Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Ampersand Biomedicines website traffic

Latest recorded traffic for Ampersand Biomedicines is 4.2K monthly website visits, down 10.6% over the last three months. Ampersand Biomedicines's team grew 20% over the past year.

Latest monthly visits4.2K 3-month web change-10.6% 1-year team growth+20%

Monthly website visitsApr 2023–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

Co-op, Protein Sciences (Spring 2027, open to Northeastern students only)Boston, Massachusetts, United States, Northern America, Americas · Other · Aug 22, 2026 Co-op, Data Engineering (Spring 2027, open to Northeastern students only)Boston, Massachusetts, United States, Northern America, Americas · Data Science & Engineering · Aug 22, 2026 Senior Scientist I, MicrofluidicsBoston, Massachusetts, United States, Northern America, Americas · Other · Jul 25, 2026 Research Associate II, Protein SciencesBoston, MA · Other · Jun 11, 2026

4 distinct openings shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
DBDelve BioProviding Molecular Insights for the Precision Care of the Sickest Patients	Boston, United States	Operational	43	$71M	$140M
NONodus OncologyNext-generation precision medicines targeting DNA damage response	Macclesfield, United Kingdom	Operational
LBLeo Summit BiotechnologyCreating a characteristic research and development platform combining "engineering center + expert think tank + postdoctoral workstation" combining production, learning and research	China	Operational
BTBonum TherapeuticsFocused on a proven technology that utilizes allosteric regulation to create targeted, highly active, and less toxic medicines	Seattle, United States	Operational
SBSalish BioscienceAn oncology diagnostics company focused on answering the question, "do I still have cancer?"	Seattle, United States	Operational
CLClovernaRNA Targeted Drug Discovery Platform	Kurashiki, Japan	Operational
STSama TherapeuticsPrecision Neuropsychiatry AI/ML platform to accelerate psychedelic-inspired R&D	Cambridge, United States	Operational
ETENSEM TherapeuticsBiotechnology company focusing on high value and difficult-to-drug oncology targets	Medford, United States	Operational